Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 5/20 | 0.52 |
| ▸ | EGLN1 | Q9GZT9 | 9/20 | 0.47 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | TET3 | O43151 | 1/20 | 0.38 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.38 |
| ▸ | VEGFA | P15692 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
| ▸ | ASPH | Q12797 | 1/20 | 0.38 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.38 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.38 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.38 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.38 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.38 |
| ▸ | TOP1 | P11387 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.36 |
| ▸ | WNT3A | P56704 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3519260 | 0.94 | EGLN3 (0.53) | EGLN3EGLN1VEGFAFLT1TOP1 | |
| SCHEMBL3761128 | 0.93 | EGLN3 (0.55) | EGLN3EGLN1ATRTET3BBOX1 | |
| SCHEMBL3520873 | 0.88 | EGLN3 (0.40) | EGLN3EGLN1ATRVEGFAFLT1 | |
| SCHEMBL3522299 | 0.87 | EGLN3 (0.60) | EGLN3EGLN1ATRTET3BBOX1 | |
| SCHEMBL3521733 | 0.87 | TOP1 (0.42) | ATRTOP1WNT3A | |
| SCHEMBL3519608 | 0.85 | EGLN3 (0.58) | EGLN3EGLN1TOP1FTO | |
| SCHEMBL3519157 | 0.85 | EGLN3 (0.47) | EGLN3EGLN1TOP1HIF1AFTO | |
| SCHEMBL3519778 | 0.85 | EGLN3 (0.57) | EGLN3EGLN1ATRTET3BBOX1 | |
| SCHEMBL3520062 | 0.84 | EGLN3 (0.49) | EGLN3EGLN1HIF1A | |
| SCHEMBL3526608 | 0.84 | EGLN3 (0.53) | EGLN3EGLN1TET3BBOX1VEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-12-02 | — | — | US | claimed |
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-12-02 | — | — | US | disclosed |
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-12-02 | — | — | US | disclosed |
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-12-02 | — | — | US | disclosed |
| WO-2009073497-A2 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | EGLN3 2/4885EGLN1 6/4885ATR 4548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.